Apomorphine in the treatment of Parkinson disease and other movement disorders

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.10, Iss.6, 2009-04, pp. : 1027-1038

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Apomorphine in the treatment of Parkinson's disease

By Menon Rukmini Stacy Mark

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 12, 2007-08 ,pp. : 1941-1950

Informa Healthcare

Access to resources Recommend Favorite

Apomorphine therapy in Parkinson's disease: a review

By Ul Haq Ihtsham Lewitt Peter A Fernandez Hubert H

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 16, 2007-11 ,pp. : 2799-2809

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic-Pharmacodynamic Relationships of Apomorphine in Patients with Parkinson's Disease

By Neef C.

Clinical Pharmacokinetics, Vol. 37, Iss. 3, 1999-09 ,pp. : 257-271

Adis International

Access to resources Recommend Favorite

Amantadine, Apomorphine and Zolpidem in the Treatment of Disorders of Consciousness

Current Pharmaceutical Design, Vol. 20, Iss. 26, 2014-08 ,pp. : 4167-4184

Bentham Science Publishers

Access to resources Recommend Favorite

Subcutaneous Apomorphine: An Evidence-Based Review of its Use in Parkinsons Disease

By Dirk Deleu

Drugs & Aging, Vol. 21, Iss. 11, 2004-01 ,pp. : 687-709

Adis International

Access to resources Recommend Favorite